Skip to Content

Tag: Belluscura


Also Noted

Belluscura nears distribution

June 28, 2021HME News Staff

LONDON – Belluscura has signed its first U.S. distribution agreement for its X-PLO2R portable oxygen concentrator portfolio. The company has issued its first purchase order, with delivery expected in the third quarter, according to reports. The X-PLO2R is a lightweight POC cleared by the U.S. Food and Drug Administration designed to replace larger, metal oxygen tanks and heavier devices. Belluscura began trading on the Alternative Investment Market (AIM) on the London Stock Exchange earlier...

Belluscura, Portable Oxygen Concentrator


Read Full Articlered right arrow icon

Vendors

Belluscura lists on London exchange

June 1, 2021HME News Staff

LONDON and PLANO, Texas – Belluscura, a medical device developer focused on lightweight and portable oxygen enrichment technology, has begun trading on the Alternative Investment Market (AIM) on the London Stock Exchange under the ticker symbol BELL.  The company has raised 17.5 million pounds supported by new and existing inventors, and it has a market cap of about 50.96 million pounds.  SPARK Advisory Partners Limited acted as the Belluscura’s sole nominated adviser...

Belluscura, investment, Portable Oxygen Concentrator


Read Full Articlered right arrow icon

News

In brief: Delivery costs, CPAP compliance, CareCentrix model 

March 12, 2021HME News Staff

WATERLOO, Iowa – The cost of delivering home medical equipment has increased during the COVID-19 pandemic, according to the results of a new survey from VGM.   The survey of nearly 100 medical equipment providers in eight regions of the U.S. looked at vehicle cost per trip; PPE expense; labor expense per hour; and time of travel, equipment set-up and instruction, and equipment pickup.  In the Great Lakes region, for example, the average delivery cost has...

Belluscura, CareCentrix, Home Medical Equipment, NCPA, Numotion, VGM


Read Full Articlered right arrow icon

Also Noted

Belluscura cleared to launch POC

March 9, 2021HME News Staff

LONDON — Tekcapital has announced that its portfolio company Belluscura has been granted 510(k) clearance and marketing authorization by the U.S. Food and Drug Administration for its X-PLO2R portable oxygen concentrator. "We are excited to see that the FDA has cleared the X-PLO2R device for sale, as Tekcapital and Belluscura believe it could be helpful to patients during the COVID-19 pandemic, and for many of the 250 million people worldwide suffering from COPD," said Clifford Gross, PhD, executive...

Belluscura, FDA clearance, Portable Oxygen Concentrator, Tekcapital


Read Full Articlered right arrow icon

Also Noted

Belluscura reaches fundraising goal for POC

April 30, 2019HME News Staff

PLANO, Texas - Belluscura has reached its fundraising goal for its portable oxygen concentrator, the X-PLO2R. The company, part of the portfolio of Tekcapital Plc, a U.K. intellectual property investment group, has raised 500,000 pounds. “We are delighted to see that Belluscura has reached its crowdfunding target of 500,000 pounds to help complete the regulatory clearance and launch of their new X-PLOR portable oxygen concentrator later this year,” said Dr. Clifford Gross, chairman of...

Belluscura, fundraising, POC


Read Full Articlered right arrow icon

Vendors

Belluscura readies to launch X-PLO2R

March 29, 2019Liz Beaulieu, Editor

PLANO, Texas - Belluscura, a U.K. company that licenses and develops proprietary healthcare technologies, plans to launch a portable oxygen concentrator named the X-PLO2R in the U.S. market in the back half of this year.In March, Belluscura, which is headquartered in Plano, Texas, was in the middle of trying to raise funds to complete the regulatory clearance process with the U.S. Food and Drug Administration and launch the unit.“We've already raised $6 million, so it's not our only source...

Belluscura, new entrant, new product, Oxygen Therapy, POC


Read Full Articlered right arrow icon